Filing Details
- Accession Number:
- 0000899243-21-047360
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-08 17:05:14
- Reporting Period:
- 2021-12-08
- Accepted Time:
- 2021-12-08 17:05:14
- SEC Url:
- Form 4 Filing
Issuer
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1618902 | Hellman & Friedman Capital Partners Viii (Parallel), L.p. | 415 Mission Street, Suite 5700 San Francisco CA 94105 | No | No | Yes | No | |
1618909 | Hfcp Viii (Parallel - A), L.p. | 415 Mission Street, Suite 5700 San Francisco CA 94105 | No | No | Yes | No | |
1618933 | Hellman & Friedman Capital Partners Viii, L.p. | 415 Mission Street, Suite 5700 San Francisco CA 94105 | No | No | Yes | No | |
1619367 | H&F Executives Viii, L.p. | 415 Mission Street, Suite 5700 San Francisco CA 94105 | No | No | Yes | No | |
1621509 | H&F Associates Viii, L.p. | 415 Mission Street, Suite 5700 San Francisco CA 94105 | No | No | Yes | No | |
1767563 | H&F Corporate Investors Viii, Ltd. | 415 Mission Street, Suite 5700 San Francisco CA 94105 | No | No | Yes | No | |
1801252 | Hellman & Friedman Investors Viii, L.p. | 415 Mission Street, Suite 5700 San Francisco CA 94105 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-12-08 | 52,884,036 | $47.50 | 0 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2021-12-08 | 20,244,387 | $47.50 | 0 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2021-12-08 | 3,630,740 | $47.50 | 0 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2021-12-08 | 359,372 | $47.50 | 0 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2021-12-08 | 35,622,429 | $47.50 | 0 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2021-12-08 | 15,987,409 | $47.50 | 0 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2021-12-08 | 3,021,286 | $47.50 | 0 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2021-12-08 | 934,469 | $47.50 | 0 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2021-12-08 | 157,138 | $47.50 | 0 | No | 4 | S | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
Footnotes
- On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash.
- Reflects securities directly held by Hellman & Friedman Capital Partners VII, L.P. ("HFCP VII").
- Reflects securities directly held by Hellman & Friedman Capital Partners VII (Parallel), L.P. ("HFCP VII Parallel").
- Reflects securities directly held by HFCP VII (Parallel-A), L.P. ("HFCP VII Parallel-A").
- Reflects securities directly held by H&F Executives VII, L.P. ("H&F VII Executives", and together with HFCP VII, HFCP VII Parallel and HFCP VII Parallel-A, the "H&F VII Funds").
- Reflects securities directly held by Hellman & Friedman Capital Partners VIII, L.P. ("HFCP VIII").
- Reflects securities directly held by Hellman & Friedman Capital Partners VIII (Parallel), L.P. ("HFCP VIII Parallel").
- Reflects securities directly held by HFCP VIII (Parallel-A), L.P. ("HFCP VIII Parallel-A").
- Reflects securities directly held by H&F Executives VIII, L.P. ("H&F VIII Executives").
- Reflects securities directly held by H&F Associates VIII, L.P. ("H&F VIII Associates", and together with HFCP VIII, HFCP VIII Parallel, HFCP VIII Parallel-A and H&F VIII Executives, the "H&F VIII Funds").
- Hellman & Friedman Investors VII, L.P. ("H&F Investors VII") is the general partner of each of the H&F VII Funds. H&F Corporate Investors VII, Ltd. ("H&F VII") is the general partner of H&F Investors VII. Hellman & Friedman Investors VIII, L.P. ("H&F Investors VIII") is the general partner of each of the H&F VIII Funds. H&F Corporate Investors VIII, Ltd. ("H&F VIII") is the general partner of H&F Investors VIII. A three member board of directors of each of H&F VII and H&F VIII has investment discretion over the shares held by the H&F VII Funds and the H&F VIII Funds, respectively. Allen R. Thorpe, a member of the board of directors of PPD, Inc. is a member of the boards of directors of H&F VII and H&F VIII.